B3GNTL1 Inhibitors
B3GNTL1 inhibitors like Tunicamycin is known to block the initial step of N-linked glycosylation, thereby potentially impacting the substrates of B3GNTL1. Similarly, Swainsonine impedes the processing of glycoproteins by inhibiting alpha-mannosidase II, which could influence the substrates available to B3GNTL1. Brefeldin A disrupts the structure of the Golgi apparatus, where B3GNTL1 is localized and functions, hence impairing its activity. On the other hand, compounds like Deoxymannojirimycin and Deoxynojirimycin act as inhibitors of mannosidase, altering the recognition and processing of B3GNTL1 substrates.
Castanospermine, an inhibitor of glucosidase, affects glycan trimming processes that are upstream of B3GNTL1's action. Kifunensine, which inhibits mannosidase I, modifies the glycan structures on the substrates that B3GNTL1 would typically process. NB-DNJ, also known as Miglustat, and Celgosivir, affect glycolipid and glycoprotein biosynthesis, respectively, with potential repercussions for B3GNTL1-mediated glycosylation. PUGNAc is a compound that modifies O-GlcNAcylation, a form of glycosylation that can alter the pathways in which B3GNTL1 operates. Nojirimycin, on the other hand, is a hexosaminidase inhibitor that might impact B3GNTL1 activity by affecting the final glycan structures on proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibitor of N-linked glycosylation, prevents the addition of oligosaccharide chains to nascent proteins, which can impair the substrate pool for B3GNTL1. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Inhibitor of Golgi alpha-mannosidase II, leads to the accumulation of misfolded glycoproteins, impacting the substrate availability for B3GNTL1. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts the structure and function of the Golgi apparatus, leading to mislocalization and functional impairment of B3GNTL1. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Inhibitor of mannosidase, alters glycan structures, potentially affecting the substrate recognition or activity of B3GNTL1. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Glucosidase inhibitor, impacts the processing of N-linked glycans, which may affect the glycosylation reactions mediated by B3GNTL1. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Inhibits glucosidase, which can prevent the proper trimming of glycan structures, thus potentially affecting B3GNTL1 activity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Inhibitor of mannosidase I, results in high-mannose glycans, which could influence B3GNTL1-mediated glycosylation. | ||||||
N-Butyldeoxynojirimycin·HCl | 210110-90-0 | sc-201398 sc-201398A sc-201398B | 5 mg 25 mg 50 mg | $180.00 $550.00 $985.00 | 4 | |
Inhibits glucosylceramide synthase, affecting glycolipid biosynthesis, which may impact B3GNTL1 function related to glycolipid glycosylation. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Blocks glucosidase I and II, which are involved in N-linked glycosylation, potentially affecting the function of B3GNTL1. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $224.00 $380.00 | 3 | |
Inhibits O-GlcNAcase, leading to altered O-GlcNAcylation levels, which may have implications for B3GNTL1-related signaling pathways. | ||||||